NewAmsterdam Pharma Company NV (NASDAQ: NAMS) on Monday, soared 3.08% from the previous trading day, before settling in for the closing price of $16.26. Within the past 52 weeks, NAMS’s price has moved between $5.63 and $26.35.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -28.76%. The company achieved an average annual earnings per share of -9.53%. With a float of $39.19 million, this company’s outstanding shares have now reached $82.47 million.
Considering the fact that the conglomerate employs 29 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 99.9%, operating margin of -1362.95%, and the pretax margin is -1246.38%.
NewAmsterdam Pharma Company NV (NAMS) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of NewAmsterdam Pharma Company NV is 56.46%, while institutional ownership is 37.50%. The most recent insider transaction that took place on Aug 20 ’24, was worth 81,350. In this transaction Chief Executive Officer of this company bought 5,000 shares at a rate of $16.27, taking the stock ownership to the 209,784 shares. Before that another transaction happened on Jun 20 ’24, when Company’s Chief Executive Officer bought 5,000 for $17.26, making the entire transaction worth $86,308. This insider now owns 204,784 shares in total.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Forecasts
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.54 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.49) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.53% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
NewAmsterdam Pharma Company NV (NAMS) is currently performing well based on its current performance indicators. A quick ratio of 9.83 was reported for the most recent quarter.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Compared to the last year’s volume of 0.26 million, its volume of 1.07 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 30.61%. Additionally, its Average True Range was 1.04.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 16.33%, which indicates a significant decrease from 47.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.27% in the past 14 days, which was higher than the 47.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.17, while its 200-day Moving Average is $17.94. Nevertheless, the first resistance level for the watch stands at $17.29 in the near term. At $17.82, the stock is likely to face the second major resistance level. The third major resistance level sits at $18.59. If the price goes on to break the first support level at $15.99, it is likely to go to the next support level at $15.22. Should the price break the second support level, the third support level stands at $14.69.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
Market capitalization of the company is 1.51 billion based on 89,977K outstanding shares. Right now, sales total 14,090 K and income totals -176,940 K. The company made 2,280 K in profit during its latest quarter, and -39,010 K in sales during its previous quarter.
